Pharmacist Cardiovascular Podcast 30m

Registration Ends:

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.

Learning Objectives

Upon successful completion of this course, learners should be able to:
1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.
2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.

Faculty

Joshua Davis Kinsey, PharmD

VP, Education
CEimpact

Disclosures:

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Zachary Cox, PharmD

Professor
Lipscomb University College of Pharmacy

Disclosures:

Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.

Course Details